A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

November 26, 2014

Primary Completion Date

June 16, 2020

Study Completion Date

June 16, 2020

Conditions
B-cell MalignanciesColorectal Cancer (CRC)Head and Neck CancerLung CancerLymphomaMelanomaOvarian CancerGlioblastoma
Interventions
DRUG

Nivolumab

specified dose and dosing schedule

DRUG

Epacadostat

oral twice daily continuous at the protocol-defined dose

DRUG

Chemotherapy

Specified dose on specified days

Trial Locations (24)

10016

NYU Cancer Center, New York

10032

Columbia University, Herbert Irving Comprehensive Cancer Center, New York

15232

University of Pittsburgh School of Medicine, Pittsburgh

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

27157

Wake Forest Medical Center Boulevard, Winston-Salem

27710

Duke University Medical Center, Durham

35294

UAB Comprehensive Cancer Center, Birmingham

37232

Vanderbilt University Medical Center, Nashville

53226

Medical College of Wisconsin, Milwaukee

57104

Sanford Research, North Sioux City

58122

Sanford Research, Fargo

66205

The University of Kansas Clinical Research Center, Fairway

77030

MD Anderson Cancer Center, Houston

78705

Texas Oncology Research, Austin

80045

University of Colorado Anschutz Medical Campus, Aurora

84106

Utah Cancer Specialists, Salt Lake City

84112

Huntsman Cancer Institute, Salt Lake City

90025

The Angeles Clinic and Research Institute, Los Angeles

90033

USC Norris Cancer Center, Los Angeles

94115

UCSF - University of California San Francisco, San Francisco

02215

Dana Farber Cancer Institute, Boston

01805

Lahey Hospital & Medical Center, Burlington

M20 4BX

The Christie NHS Foundation Trust, Manchester

OX3 7LJ

Oxford University Hospitals NHS Trust, Oxford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Incyte Corporation

INDUSTRY